Scroll Top

Valérie Taly ranked among the “palmarès des inventeurs” 2024 for METHYS Dx

The 2024 inventors’ prize list, initiated by the French magazine Le Point, has been published. An exceptional jury selected “the 100 leading teams whose research will change our lives“, including Valérie Taly for the start-up METHYS Dx, in the biotech category. The awards ceremony took place at the Paris-Saclay Summit on March 1.

This distinction rewards the efforts of the entire METHYS Dx team, which is developing an innovative diagnostic solution for monitoring cancer patients, using a simple blood test (liquid biopsy) to assess the effectiveness of treatments and detect recurrences. Created in 2021 with the support of SATT Erganeo, the start-up capitalizes on over a decade of collaborative work by the MEPPOT (CARPEM team 1 at the Cordeliers Research Center) and SPM (molecular system and programming, Gulliver Laboratory, ESPCI) teams, with the support of their institutions (AP-HP, Université Paris Cité, Sorbonne Université, Université PSL, Inserm and the CNRS).

About METHYS Dx
METHYS Dx offers an innovative diagnostic solution for monitoring cancer patients, using a simple blood test (liquid biopsy) to assess the effectiveness of treatments and detect recurrences. The start-up’s ambition is to become a major player in oncology diagnostics, thanks to its non-invasive cancer detection and characterization tools, which will in future help to improve the management of cancer patients. 
METHYS Dx was co-founded by Drs Pierre Laurent-Puig (PU-PH, AP-HP/Université Paris Cité), Guillaume Gines (CNRS researcher), Benjamin Nayagom (PhD trained at MEPPOT laboratory), Yannick Rondelez (CNRS research director) and Valérie Taly (CNRS research director). The start-up is managed by Valérie Taly (President/CSO) and Magali Droniou (CEO).